Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Robert Brudevold"'
Publikováno v:
PLoS ONE, Vol 3, Iss 10, p e3547 (2008)
OBJECTIVE: During the last 10 years we have experienced an increasing number of referrals due to hyperferritinemia. This is probably due to increased awareness of hereditary hemochromatosis, and the availability of a genetic test for this condition.
Externí odkaz:
https://doaj.org/article/37889ea719f34b2d9972ffc631d3b16a
Publikováno v:
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke. 140(18)
Eosinophilic granulomatosis with polyangiitis (EGPA) is a multisystem disorder characterised by chronic rhinosinusitis, asthma, and pronounced peripheral blood eosinophilia. The most commonly involved organ is the lung. However, EGPA can affect any o
Autor:
Anders E.A. Dahm, Eirik Brekka Tjønnfjord, Galina Tsykunova, Pernille H. Jæger, Henrik Hjorth-Hansen, Hege Frøen, Megan Kell, Robert Brudevold, Jürgen Rolke, Randi Fykse Hallstensen, Agnieszka Malecka, Markku Oksman, Sigbjørn Berentsen, Ulla Randen, Jakob Dalgaard, Einar Haukås, Mallika Sekhar, Tor Henrik Anderson Tvedt, Wilma Barcellini, Bruno Fattizzo, Shirley D'Sa, Geir E. Tjønnfjord, Jon Hjalmar Sørbø
Publikováno v:
Blood. 136(4)
We retrospectively studied 232 patients with cold agglutinin disease (CAD) at 24 centers in 5 countries. In Norway and a northern region of Italy, the study was close to being population-based. For the first time, we demonstrate fourfold differences
Autor:
K. Thorstensen, Robert Brudevold, Ø. O. Langseth, Geir E. Tjønnfjord, Petter Quist-Paulsen, J. A. Kremer Hovinga, A. S. von Krogh, Carlo R. Largiadèr, Bernhard Lämmle, Anders Waage
Publikováno v:
Journal of thrombosis and haemostasis : JTH
Essentials The population prevalence of hereditary thrombotic thrombocytopenic purpura (TTP) is unknown. We studied the prevalence of hereditary TTP and population frequencies of two ADAMTS-13 mutations. A high frequency of hereditary TTP related to
Autor:
Robert Brudevold, Aleksei Ogarkov, Petter Quist-Paulsen, Paul Anders Sletten Olsen, Øystein Brenna
Publikováno v:
Tidsskrift for Den norske legeforening.
Autor:
Einar Haukås, Jakob Dalgaard, Eivind Galteland, Jon Hjalmar Sørbø, Ulla Randen, Henrik Birgens, Agnieszka Malecka, Sigbjørn Berentsen, Tor Henrik Anderson Tvedt, Inger Anne Næss, Geir E. Tjønnfjord, Markku Oksman, Robert Brudevold
Publikováno v:
Blood. 130(4)
Primary chronic cold agglutinin disease (CAD) is a well-defined clinicopathologic entity in which a bone marrow clonal B-cell lymphoproliferation results in autoimmune hemolytic anemia and cold-induced circulatory symptoms. Rituximab monotherapy and
Autor:
Boris Spahic, Waleed Ghanima, Jens Hammerstrøm, Therese Valebjørg, Fredrik Bremtun, Robert Brudevold, Johannes Kahrs, Jan Kolflaath
Publikováno v:
European journal of haematology. 93(4)
The study objectives were to determine the intensity and duration of pain, factors that may influence pain experience during and after trephine biopsy, and to assess bleeding and infectious complications related to the procedure. Patients scheduled f
Autor:
Ruth Langholm, Sigbjørn Berentsen, Robert Brudevold, Bjørn Tore Gjertsen, Elling Ulvestad, Erik Løkkevik, Jon Hjalmar Sørbø, Geir E. Tjønnfjord
Publikováno v:
British Journal of Haematology. 115:79-83
The ‘primary’ form of chronic cold agglutinin disease is a clonal B-cell lymphoproliferative disorder that is notoriously difficult to treat with drugs, including corticosteroids, alkylating agents, alpha-interferon and purine analogues. We perfo
Publikováno v:
PLoS ONE, Vol 3, Iss 10, p e3547 (2008)
PLoS ONE
PLoS ONE
Objective: During the last 10 years we have experienced an increasing number of referrals due to hyperferritinemia. This is probably due to increased awareness of hereditary hemochromatosis, and the availability of a genetic test for this condition.
Autor:
Jens, Hammerstrøm, Irene Line, Aasland, Ragnar, Telhaug, Torolf, Moen, Bottolf, Lødemel, Yngve, Sørum, Robert, Brudevold, Oluf, Herlofsen, Jon Hjalmar, Sørbø, Turid, Almvik, Jon, Lamvik
Publikováno v:
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke. 124(19)
The introduction of high-dose treatment with autologous stem cell support (HMAS) in Norwegian regional hospitals in the early 1990s was controversial. Concerns that low numbers of patients would lead to unacceptably low quality were expressed.We pres